Xencor traded at $30.34 this Wednesday August 17th, decreasing $0.67 or 2.16 percent since the previous trading session. Looking back, over the last four weeks, Xencor lost 0.90 percent. Over the last 12 months, its price fell by 4.38 percent. Looking ahead, we forecast Xencor to be priced at 29.62 by the end of this quarter and at 27.20 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 141.49 0.05 0.04% 20.63%
Alnylam Pharmaceuticals 223.13 -5.02 -2.20% 12.96%
Amgen 248.73 -1.85 -0.74% 9.65%
Arrowhead Research 45.88 -1.75 -3.67% -23.24%
AstraZeneca 11,026.00 24.00 0.22% 26.21%
Biogen 216.32 -1.27 -0.58% -36.73%
Bristol-Myers Squibb 74.30 -0.26 -0.35% 8.45%
Cytokinetics 50.57 -0.24 -0.47% 67.17%
GlaxoSmithKline 1,415.00 -0.40 -0.03% -6.51%
J&J 167.25 -0.33 -0.20% -5.61%
Karyopharm Therapeutics 5.08 -0.22 -4.15% 7.40%
MacroGenics 4.36 -0.14 -3.01% -80.22%
Merck & Co 91.14 0.10 0.11% 17.16%
Novartis 81.35 0.12 0.15% -4.75%
Pfizer 49.02 -0.25 -0.51% -0.59%
Regeneron Pharmaceuticals 631.89 -4.45 -0.70% -3.62%
Roche Holding 319.10 2.45 0.77% -14.22%
Seattle Genetics 170.79 0.27 0.16% 7.57%
Xencor 30.34 -0.67 -2.16% -4.38%

Indexes Price Day Year
USND 12907 -31.43 -0.24% -11.24%
US2000 1987 -0.75 -0.04% -6.84%

Xencor
Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.